- Trials with a EudraCT protocol (39,323)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (14,969)
39,323 result(s) found for: 1.
Displaying page 509 of 1,967.
| EudraCT Number: 2019-000698-22 | Sponsor Protocol Number: MK-7339-003 | Start Date*: 2020-02-26 | |||||||||||
| Sponsor Name:Merck Sharp & Dohme LLC | |||||||||||||
| Full Title: A Phase 3 Randomized, Open-label Study to Evaluate the Efficacy and Safety of Olaparib Alone or in Combination With Bevacizumab Compared to Bevacizumab with a Fluoropyrimidine in Participants with ... | |||||||||||||
| Medical condition: The treatment of participants with unresectable or metastatic CRC that has not progressed following an induction course of FOLFOX + bevacizumab | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: BE (Completed) HU (Completed) FR (Completed) LT (Completed) LV (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2022-003400-32 | Sponsor Protocol Number: TAK-664-3002 | Start Date*: 2022-11-21 |
| Sponsor Name:Takeda | ||
| Full Title: A Phase 3, Open-label, Non-controlled, Multi-dose, Extension Study to Evaluate the Long-term Safety and Tolerability of IGSC, 20% in Japanese Participants with Primary Immunodeficiency Disease (PID) | ||
| Medical condition: Primary immunodeficiency diseases (PID) | ||
| Disease: | ||
| Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | |
| Trial protocol: Outside EU/EEA | ||
| Trial results: View results | ||
| EudraCT Number: 2018-004150-13 | Sponsor Protocol Number: 30032016 | Start Date*: 2018-12-20 | |||||||||||
| Sponsor Name:Zealand University hospital | |||||||||||||
| Full Title: Combination Therapy with Interferon-Alpha2a and Ruxolitinib in Newly Diagnosed Patients with Polycythemia Vera. A Danish Safety and Efficacy Study. | |||||||||||||
| Medical condition: Polycythemia Vera | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: DK (Trial now transitioned) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2020-005037-32 | Sponsor Protocol Number: PSIKET_002CZE | Start Date*: 2021-09-22 | |||||||||||
| Sponsor Name:Národní ústav duševního zdraví | |||||||||||||
| Full Title: Psilocybin - a strategy of rapid antidepressant response in depression comorbid with cancer, a randomized double-blind study with the possibility of entering open extension. | |||||||||||||
| Medical condition: Depressive disorder comorbid with cancer | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: CZ (Trial now transitioned) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2021-004278-76 | Sponsor Protocol Number: GINECO-OV129b | Start Date*: 2021-11-22 | |||||||||||
| Sponsor Name:ARCAGY-GINECO | |||||||||||||
| Full Title: A Randomized Study of Paclitaxel – Carboplatin followed by maintenance Niraparib compared to Paclitaxel – Carboplatin – Bevacizumab followed by maintenance Niraparib + Bevacizumab in Patients With... | |||||||||||||
| Medical condition: Advanced ovarian, tubal or peritoneal cancer | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Female | ||||||||||||
| Trial protocol: FR (Trial now transitioned) ES (Ongoing) IT (Trial now transitioned) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2011-000397-59 | Sponsor Protocol Number: none | Start Date*: 2011-03-21 |
| Sponsor Name: | ||
| Full Title: Prevention of post-ERCP acute pancreatitis by heme-oxygenase activation through the administration of hemin: a prospective, randomized double blind controlled trial. | ||
| Medical condition: Prevention of post-ERCP acute pancreatitis. So, patient with indications of ERCP (endoscopic retrograde cholangiopanreatography) will be included. These patients suffer from bilio-pancreatic disord... | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: BE (Completed) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2021-002322-24 | Sponsor Protocol Number: SOLTI-1911 | Start Date*: 2022-03-10 |
| Sponsor Name:SOLTI | ||
| Full Title: Neoadjuvant and adjuvant RIBOciclib and endocrine therapy for cLinicAlly high-RISk estrogen receptor-positive (ER+) and HER2-negative (HER2-) breast cancer (RIBOLARIS) | ||
| Medical condition: Patients with primary operable stage II, grade 2 or 3, Ki67 ≥20%, HR+/HER2- breast cancer to evaluate safety and long-term efficacy of a non-chemo treatment in patients biologically responders to n... | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: ES (Ongoing) FR (Trial now transitioned) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2015-001663-39 | Sponsor Protocol Number: D4190C00022 | Start Date*: 2015-11-27 | |||||||||||
| Sponsor Name:MedImmune | |||||||||||||
| Full Title: A Study of Safety, Tolerability, and Clinical Activity of MEDI4736 and Tremelimumab Administered as Monotherapy and in Combination to Subjects with Unresectable Hepatocellular Carcinoma | |||||||||||||
| Medical condition: Hepatocellular Carcinoma | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: ES (Completed) IT (Trial now transitioned) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2022-003905-31 | Sponsor Protocol Number: RF-2021-12372278 | Start Date*: 2023-07-14 | |||||||||||
| Sponsor Name:OSPEDALE SAN RAFFAELE | |||||||||||||
| Full Title: Fully hybrid 18F-PSMA PET/MRI as one-stop approach for the diagnosis of clinically significant prostate cancer | |||||||||||||
| Medical condition: Patients with clinical suspicion of clinically relevant prostate cancer | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male | ||||||||||||
| Trial protocol: IT (Trial now transitioned) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2019-000111-84 | Sponsor Protocol Number: ACE-LY-003 | Start Date*: 2020-02-04 | |||||||||||||||||||||
| Sponsor Name:ACERTA PHARMA BV | |||||||||||||||||||||||
| Full Title: An Open-label, Phase 1b/2 Study of Acalabrutinib Alone or in Combination Therapy in Subjects with B-cell Non-Hodgkin Lymphoma | |||||||||||||||||||||||
| Medical condition: B-cell Non-Hodgkin Lymphoma | |||||||||||||||||||||||
|
|||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
| Trial protocol: IT (Trial now transitioned) | |||||||||||||||||||||||
| Trial results: (No results available) | |||||||||||||||||||||||
| EudraCT Number: 2021-002126-24 | Sponsor Protocol Number: SEP380-301 | Start Date*: 2022-02-02 | |||||||||||
| Sponsor Name:Sunovion Pharmaceuticals Inc. | |||||||||||||
| Full Title: A Multi-region, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Evaluating SEP-4199 Controlled Release (CR) for the Treatment of Major Depressive Episode Associated ... | |||||||||||||
| Medical condition: Major Depressive Episode Associated with Bipolar I Disorder | |||||||||||||
|
|||||||||||||
| Population Age: Adults | Gender: Male, Female | ||||||||||||
| Trial protocol: BG (Prematurely Ended) SK (Prematurely Ended) HR (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2021-005309-28 | Sponsor Protocol Number: APHP200031 | Start Date*: 2023-04-07 |
| Sponsor Name:Assistance Publique des Hôpitaux de Paris | ||
| Full Title: Efficacy of certolizumab in women with unexplained recurrent implantation failure: a double-blind randomized controlled trial - CERTIFY | ||
| Medical condition: Adult women with recurrent implantation failures | ||
| Disease: | ||
| Population Age: Adults | Gender: Female | |
| Trial protocol: FR (Trial now transitioned) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2011-003124-12 | Sponsor Protocol Number: B-40320109424 | Start Date*: 2012-10-30 |
| Sponsor Name:Cliniques Universitaires Saint Luc | ||
| Full Title: A prospective phase II study on dose escalation using PET based adaptive IMRT stage II-III non small lung cancer | ||
| Medical condition: Stage II-III Non small lung cancer | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: BE (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2022-002311-39 | Sponsor Protocol Number: 101069207 | Start Date*: 2022-09-07 |
| Sponsor Name:University Of Cyprus | ||
| Full Title: Phase II trial for the use of ketotifen to enhance therapy in patients with sarcoma receiving standard chemotherapy | ||
| Medical condition: Patients with sarcoma | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: CY (Completed) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2021-004917-38 | Sponsor Protocol Number: EAE115 | Start Date*: 2022-06-28 | |||||||||||
| Sponsor Name:Hellenic Society of Hematology (EAE) | |||||||||||||
| Full Title: A Phase 2 Study of Isatuximab in combination with Pomalidomide and Dexamethasone in MM Patients who received one prior line of therapy containing Lenalidomide and a Proteasome Inhibitor | |||||||||||||
| Medical condition: Multiple myeloma patients who received one prior line of therapy containing Lenalidomide and a Proteasome Inhibitor. | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: GR (Trial now transitioned) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2008-004106-13 | Sponsor Protocol Number: NORDCML006 | Start Date*: 2009-03-23 | |||||||||||
| Sponsor Name:University of Trondheim, NTNU, Norway | |||||||||||||
| Full Title: An Open-Label, Randomized, Multicenter Phase II Trial Comparing the Depletion of Malignant Stem Cells with Dasatinib vs. Imatinib in Patients with Newly Diagnosed Chronic Phase Chronic Myeloid Leuk... | |||||||||||||
| Medical condition: Chronic myeloid leukemia (CML) in chronic phase (CP) at diagnosis (untreated) | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: SE (Completed) FI (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2013-001525-10 | Sponsor Protocol Number: bins1 | Start Date*: 2013-07-30 |
| Sponsor Name:Erasmus MC | ||
| Full Title: Studying the metabolism of sorafenib (Nexavar®) by OATP1B blockage in adult cancer patients | ||
| Medical condition: Cancer | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: NL (Completed) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2009-016502-16 | Sponsor Protocol Number: PML_DOC_0905_/_ISSSYMB0020 | Start Date*: 2009-12-02 |
| Sponsor Name:University Hospital Antwerp : Department Respiratory Medicine | ||
| Full Title: A randomized, double-blind, placebo-controlled, two way cross-over study to assess the particle deposition and acute effects of formoterol and budesonide combination therapy (Symbicort® forte Turbo... | ||
| Medical condition: COPD | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: BE (Completed) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2015-004846-25 | Sponsor Protocol Number: Pfizer-Prevenar13-2015 | Start Date*: 2016-07-15 |
| Sponsor Name:Maastricht University | ||
| Full Title: Immunization against oxLDL in patients with lysosomal lipid diseases and associated metabolic disorders | ||
| Medical condition: Familial hypercholesterolemia Niemann-Pick disease type B (NPB) Niemann-Pick disease type C (NPC) Partial lipodystrophy in children and adults | ||
| Disease: | ||
| Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | |
| Trial protocol: BE (Completed) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2020-002489-15 | Sponsor Protocol Number: 380119 | Start Date*: 2021-03-23 | |||||||||||
| Sponsor Name:Medinova AG | |||||||||||||
| Full Title: Comparative study of the efficacy and safety of vaginally applied Dequalinium Chloride (10 mg) and orally applied Metronidazole (2 x 500 mg) in the treatment of bacterial vaginosis | |||||||||||||
| Medical condition: Bacterial vaginosis | |||||||||||||
|
|||||||||||||
| Population Age: Adults | Gender: Female | ||||||||||||
| Trial protocol: CZ (Prematurely Ended) SK (Prematurely Ended) | |||||||||||||
| Trial results: View results | |||||||||||||
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
| Download Options: | |
|---|---|
| Number of Trials to download: | |
| Download Content: | |
| Download Format: | |
| Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. | |
Query did not match any studies.